AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31096476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroidism subgroup
Number of subjects: 0
Study 31096476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism subgroup
Number of subjects: 0
Study 31096476 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid disease patients without comorbidity
Number of subjects: 0
Study 31096476 — intervention group
Group type: COMPARATOR
Intervention: Thyroid disease group
Number of subjects: 0
Study 28291262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (0.5, 1.0 or 2.0 mg twice daily)
Number of subjects: 88
Study 28291262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25477074 — intervention group
Group type: EXPERIMENTAL
Intervention: NFB + TAU
Number of subjects: 71
Study 25477074 — intervention group
Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 71
Study 23668330 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RPostC)
Number of subjects: 69
Study 23668330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 21078615 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC1779 (83 and 250 nmol/L)
Number of subjects: 0
Study 21078615 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (100 nmol/L)
Number of subjects: 0
Study 21078615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19156121 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (M) 5 mg daily for 1 week, then 10 mg daily for 1 week, then 15 mg daily for 1 week, then 20 mg daily from the 4th week
Number of subjects: 15
Study 19156121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no memantine)
Number of subjects: 15
Study 16820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 4 weeks
Number of subjects: 120
Study 16820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 8 weeks
Number of subjects: 120
Study 16820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 12 weeks
Number of subjects: 120
Study 16820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 16 weeks
Number of subjects: 120
Study 12669393 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 0
Study 12669393 — intervention group
Group type: COMPARATOR
Intervention: Single fraction radiotherapy
Number of subjects: 0
Study 12669393 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field hemibody irradiation or systemic administration of radioisotopes
Number of subjects: 0
Study 11783142 — intervention group
Group type: EXPERIMENTAL
Intervention: Baoyuan Qiangshen Capsule No. II (BYQS) combined with Lotensin
Number of subjects: 60
Study 11783142 — intervention group
Group type: COMPARATOR
Intervention: Essential amino acid combined with Lotensin
Number of subjects: 60
Study 7557097 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 7557097 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 0
Study 2196622 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone (100 mg to 200 mg daily)
Number of subjects: 0
Study 490852 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate
Number of subjects: 271
Study 490852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 31177325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass-filtered Word Stress Pattern (WSP-LPF) test
Number of subjects: 36
Study 31177325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence test with adaptive randomized roving level (STARR) test
Number of subjects: 36
Study 31177325 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 36
Study 28880941 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day educational program for health workers in intravenous treatment
Number of subjects: 330
Study 28880941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics in nursing homes
Number of subjects: 330
Study 28880941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids in nursing homes
Number of subjects: 330
Study 24861418 — intervention group
Group type: EXPERIMENTAL
Intervention: Free reflective, fluorescent vests provided to 90 drivers in the intervention arm.
Number of subjects: 180
Study 24861418 — intervention group
Group type: COMPARATOR
Intervention: No vests provided to 90 drivers in the control arm.
Number of subjects: 180
Study 21817118 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factor screening program
Number of subjects: 118
Study 19640363 — intervention group
Group type: EXPERIMENTAL
Intervention: Market capsule formulation
Number of subjects: 24
Study 19640363 — intervention group
Group type: EXPERIMENTAL
Intervention: Market suspension
Number of subjects: 24
Study 19640363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial suspension
Number of subjects: 24
Study 19640363 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (market suspension, clinical trial suspension, market capsule)
Number of subjects: 24
Study 17635595 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg twice daily for 6 days
Number of subjects: 633
Study 17635595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 15288975 — intervention group
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl 0.15%
Number of subjects: 1131
Study 15288975 — intervention group
Group type: COMPARATOR
Intervention: timolol maleate 0.5%
Number of subjects: 1131
Study 15288975 — intervention group
Group type: COMPARATOR
Intervention: betaxolol hydrochloride 0.5%
Number of subjects: 1131
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial asthma patients during exacerbations (n=24)
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients at onset of illness (n=52)
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: IPF patients (n=21)
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial asthma patients after 3 weeks of treatment with oral glucocorticoids (n=20)
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients after 3 weeks with clinical improvement (n=20)
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CRP with Hb-CO in pneumonia patients
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CRP with Hb-CO in IPF patients
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Hb-CO with FEV(1) in bronchial asthma patients after 3 weeks
Number of subjects: 151
Study 12200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of exhaled CO with Hb-CO concentrations (n=33)
Number of subjects: 151
Study 12200522 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects (n=34)
Number of subjects: 151
Study 9866667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin cream applied topically 3 times daily
Number of subjects: 706
Study 9866667 — intervention group
Group type: COMPARATOR
Intervention: Oral cephalexin given 4 times daily
Number of subjects: 706
Study 7622767 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/m2 IFN-gamma treatment
Number of subjects: 16
Study 7622767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionomycin plus phorbol ester stimulation
Number of subjects: 16
Study 7622767 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 16
Study 2646083 — intervention group
Group type: EXPERIMENTAL
Intervention: Valtrac biofragmentable anastomotic ring (BAR)
Number of subjects: 438
Study 2646083 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture techniques
Number of subjects: 438
Study 2646083 — intervention group
Group type: COMPARATOR
Intervention: Stapling techniques
Number of subjects: 438
Study 32041 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg i.v.)
Number of subjects: 33
Study 32041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunitrolol (10 mg i.v.)
Number of subjects: 33
Study 32041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (10 mg i.v.)
Number of subjects: 33
Study 32041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 33
Study 31683183 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn group (real upper limb burn injury)
Number of subjects: 30
Study 31683183 — intervention group
Group type: COMPARATOR
Intervention: Simulated group (elbow flexed at 90° with a bandage)
Number of subjects: 30
Study 31683183 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal arm swing)
Number of subjects: 30
Study 31672132 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 μg/d)
Number of subjects: 70
Study 31672132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28233921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐psychosocial Intervention (BPSI) coping skills class
Number of subjects: 120
Study 28233921 — intervention group
Group type: COMPARATOR
Intervention: Standard of cancer and follow‐up care (SOC)
Number of subjects: 120
Study 25725940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with dehydrated egg white
Number of subjects: 31
Study 25725940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23823951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable plates
Number of subjects: 69
Study 23823951 — intervention group
Group type: COMPARATOR
Intervention: Titanium plates
Number of subjects: 69
Study 21859559 — intervention group
Group type: EXPERIMENTAL
Intervention: PHY906
Number of subjects: 0
Study 21859559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PHY906 with irinotecan, 5‐fluorouracil (5‐FU), and leucovorin (LV)
Number of subjects: 0
Study 19476594 — intervention group
Group type: EXPERIMENTAL
Intervention: Deity Yoga meditation
Number of subjects: 0
Study 19476594 — intervention group
Group type: COMPARATOR
Intervention: Open Presence meditation
Number of subjects: 0
Study 19476594 — intervention group
Group type: COMPARATOR
Intervention: Control groups (resting or performing other visuospatial tasks)
Number of subjects: 0
Study 17874238 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg daily)
Number of subjects: 15
Study 17874238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16872529 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated clothes (ITCs)
Number of subjects: 198
Study 16872529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 198
Study 12589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-outside group
Number of subjects: 3
Study 12589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-inside group
Number of subjects: 3
Study 12589447 — intervention group
Group type: EXPERIMENTAL
Intervention: Near group
Number of subjects: 3
Study 12589447 — intervention group
Group type: COMPARATOR
Intervention: Internal-focus control group
Number of subjects: 3
Study 10523747 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance measures
Number of subjects: 0
Study 10523747 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models for compliance data
Number of subjects: 0
Study 10523747 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures data on compliance and response
Number of subjects: 0
Study 8694355 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (0.5% bupivacaine with epinephrine) after surgery
Number of subjects: 120
Study 8694355 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (0.5% bupivacaine with epinephrine) before surgery
Number of subjects: 120
Study 8694355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml 0.9% saline)
Number of subjects: 120
Study 1683880 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program based on the arousal‐attribution stress model
Number of subjects: 76
Study 6755389 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐Amsa (200 mg/m2 x 5 days) with Ara‐C (200 mg/m2 x 5 days)
Number of subjects: 91
Study 6755389 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐Amsa (200 mg/m2 x 5 days)
Number of subjects: 91
Study 6755389 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐Amsa (120 mg/m2 x 7 days) with Ara‐C (200 mg/m2 x 5 days)
Number of subjects: 91
Study 6755389 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐Amsa (high doses)
Number of subjects: 91
Study 6755389 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐Amsa (high doses) with Ara‐C (high doses)
Number of subjects: 91
Study 6755389 — intervention group
Group type: COMPARATOR
Intervention: Previous high doses of anthracyclins
Number of subjects: 91
Study 30499637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 48
Study 28095813 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation augmented with cognitive behaviour therapy (CBT)
Number of subjects: 148
Study 28095813 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation augmented with cognitive remediation (CR)
Number of subjects: 148
Study 28095813 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 148
Study 26051510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to WCRF/AICR recommendations (low, moderate, high)
Number of subjects: 275
Study 23416514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (PI) for 15 seconds
Number of subjects: 131
Study 23416514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (PI) for 30 seconds or more
Number of subjects: 131
Study 23416514 — intervention group
Group type: COMPARATOR
Intervention: Lid speculum placement
Number of subjects: 131
Study 21285135 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning group (n=106)
Number of subjects: 211
Study 21285135 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=105)
Number of subjects: 211
Study 18635693 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.6 mg/kg b.wt.)
Number of subjects: 15
Study 18635693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg)
Number of subjects: 15
Study 18635693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 17873500 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics with adrenaline
Number of subjects: 39
Study 17873500 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetics without adrenaline
Number of subjects: 39
Study 15326236 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days, followed by 10 mg/day as per clinician's judgment)
Number of subjects: 290
Study 15326236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 15326236 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 290
Study 11561261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (air-buffered injections, n = 25)
Number of subjects: 44
Study 11561261 — intervention group
Group type: COMPARATOR
Intervention: Group II (conventional injections, n = 19)
Number of subjects: 44
Study 9626821 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 23
Study 9626821 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 23
Study 7946492 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkworker intervention (encouragement and explanations about breast screening)
Number of subjects: 0
Study 7946492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visits)
Number of subjects: 0
Study 2884547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate
Number of subjects: 18
Study 31736381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg oral daily
Number of subjects: 28
Study 31736381 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (no drug)
Number of subjects: 28
Study 31789961 — intervention group
Group type: EXPERIMENTAL
Intervention: Training according to Comfort Theory
Number of subjects: 68
Study 31789961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study 30665435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectoral and multimodal intervention for preventing delirium
Number of subjects: 1500
Study 27285965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 25 µg
Number of subjects: 622
Study 27285965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 50 µg
Number of subjects: 622
Study 27285965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 100 µg
Number of subjects: 622
Study 27285965 — intervention group
Group type: COMPARATOR
Intervention: Fp DPI 100 µg
Number of subjects: 622
Study 27285965 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 622
Study 25972254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent with cataract surgery (CS)
Number of subjects: 100
Study 25972254 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery (CS) alone
Number of subjects: 100
Study 23507227 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (800 μg) and vitamin B(12) (1000 μg)
Number of subjects: 31
Study 23507227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21300255 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy-facilitated orthodontics
Number of subjects: 13
Study 21300255 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticotomy)
Number of subjects: 13
Study 19338157 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Xuefu Zhuyu Capsule (XFZYC)
Number of subjects: 60
Study 19338157 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (Control)
Number of subjects: 60
Study 18043171 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin eyedrops
Number of subjects: 16
Study 18043171 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 16
Study 15138424 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRFTA treatment (3 tongue treatments)
Number of subjects: 26
Study 15138424 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRFTA treatment (2 additional tongue and palate treatments)
Number of subjects: 26
Study 12101577 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 266
Study 12101577 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-analog laser procedure (WHO)
Number of subjects: 266
Study 10223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin alone (treatment A)
Number of subjects: 24
Study 10223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin alone (treatment D)
Number of subjects: 24
Study 10223915 — intervention group
Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide 2 h before gatifloxacin (treatment B)
Number of subjects: 24
Study 10223915 — intervention group
Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide concomitant with gatifloxacin (treatment C)
Number of subjects: 24
Study 10223915 — intervention group
Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide 2 h after gatifloxacin (treatment E)
Number of subjects: 24
Study 10223915 — intervention group
Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide 4 h after gatifloxacin (treatment F)
Number of subjects: 24
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.10 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.39 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propofol 0.63 mg/kg and Ketamine 0.21 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.85 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.66 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propofol 1.05 mg/kg and Ketamine 0.35 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.61 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine greater than 0.85 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propofol 1.50 mg/kg and Ketamine 0.50 mg/kg
Number of subjects: 180
Study 7879932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propofol and Ketamine
Number of subjects: 180
Study 7879932 — intervention group
Group type: COMPARATOR
Intervention: All groups (Propofol, Ketamine, Combination)
Number of subjects: 180
Study 2095311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing purified endo-alpha-1, 3 glucanase (mutanase)
Number of subjects: 22
Study 2095311 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 22
Study 701072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lioresal (antispasticity drug)
Number of subjects: 13
Study 701072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30601452 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐001HR (17β‐estradiol and progesterone combined in a single, oral, softgel capsule)
Number of subjects: 726
Study 30601452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 30601452 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐001HR
Number of subjects: 726
Study 27312565 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink A (less sugar, no taurine)
Number of subjects: 80
Study 27312565 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink B (caffeine, undetermined energy blend)
Number of subjects: 80
Study 27312565 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink C (caffeine, undetermined energy blend)
Number of subjects: 80